Source comparison
MOTS-c Comparison: Mechanisms vs Other Metabolic Peptides
MOTS-c AMPK activation + nuclear translocation under stress Insulin sensitivity, metabolic flexibility, mitochondrial biogenesis 4–6 hours Only mitochondrial-encoded peptide with direct nuclear gene regulation Moderate (Phase I/II human trials) Humanin Binds t
This comparison does not assign a generated winner or score.
- MOTS-c
- AMPK activation + nuclear translocation under stress
- Insulin sensitivity, metabolic flexibility, mitochondrial biogenesis
- 4–6 hours
- Only mitochondrial-encoded peptide with direct nuclear gene regulation
- Moderate (Phase I/II human trials)
- Humanin
- Binds to IGFBP-3, modulates apoptosis, protects against oxidative stress
- Neuroprotection, cardiovascular protection, insulin sensitivity
- 2–3 hours
- Strongest anti-apoptotic signal among mitochondrial peptides
- High (multiple Phase II trials completed)
- SS-31 (Elamipretide)
- Binds cardiolipin on inner mitochondrial membrane, stabilises cristae structure
- Mitochondrial membrane potential, ATP production, ROS reduction
- 3–5 hours
- Only peptide targeting cardiolipin-cytochrome c interaction directly
- High (FDA orphan drug designation for Barth syndrome)
- GLP-1 Agonists (Semaglutide, Tirzepatide)
- GLP-1 receptor activation, delayed gastric emptying, appetite suppression
- Weight loss, glycemic control, cardiovascular risk reduction
- 5–7 days (weekly formulations)
- FDA-approved for obesity and T2DM; proven clinical efficacy
- Very high (widespread clinical use)
- Metformin
- AMPK activation via mitochondrial complex I inhibition
- Hepatic glucose output, insulin sensitivity
- Decades of safety data; first-line T2DM treatment
- Very high (generic medication)
- The comparison table illustrates that MOTS-c occupies a distinct niche among metabolic interventions. Unlike GLP-1 agonists, which work through receptor-mediated appetite suppression, MOTS-c acts at the cellular energy production level. Unlike metformin, which activates AMPK indirectly by inhibiting complex I (creating an energy deficit), MOTS-c appears to activate AMPK through a positive signaling mechanism. Without impairing mitochondrial respiration. This distinction matters: metformin's mitochondrial inhibition can reduce maximal exercise capacity in some individuals, whereas MOTS-c administration enhances it.